Arcutis Biotherapeutics, Inc.

ARQT

US03969K1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
8.59 ^USD	-1.83%		-9.10%	+165.94%

Apr. 10	Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes	CI
Mar. 18	Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index	CI

Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) dropped from Russell 3000E Value Index

June 24, 2022 at 12:00 am EDT

Latest news about Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes	Apr. 10	CI
Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Arcutis Promotes Todd Tucker to Chief Human Resources Officer	Mar. 11	CI
Arcutis Biotherapeutics Says Atopic Dermatitis Cream Met Primary Endpoint in Phase 3 Study in Children	Mar. 11	MT
Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting	Mar. 10	CI
Arcutis Biotherapeutics Raises $172.5 Million in Common Stock Offering	Mar. 04	MT
Arcutis Plans $150 Million Offering, Signs Collaboration, Licensing Deal for Roflumilast in Japan; Shares Fall After Hours	Feb. 28	MT
Mizuho Securities Raises Price Target on Arcutis Biotherapeutics to $17 From $16, Maintains Buy Rating	Feb. 28	MT
Needham Raises Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating	Feb. 28	MT
Transcript : Arcutis Biotherapeutics, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
North American Morning Briefing : Stock Futures Pause as Investors Eye Inflation Data	Feb. 27	DJ
Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Posts Q4 Revenue $13.5M, vs. Street Est of $11.4M	Feb. 27	MT
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Mizuho Increases Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating	Feb. 23	MT
Arcutis Biotherapeutics, Inc. Announces Publication of Positive Results from the Pivotal Phase 3 Trial Evaluating ZORYVE (roflumilast) Foam	Jan. 29	CI
Transcript : Arcutis Biotherapeutics, Inc. - Special Call	Jan. 22
Arcutis Biotherapeutics Launches ZORYVE Topical Foam to Treat Seborrheic Dermatitis	Jan. 22	MT
Arcutis Biotherapeutics, Inc. Announces New Subgroup Analysis Highlighting That Adults and Adopts ZoryVE Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids	Jan. 14	CI
Arcutis Biotherapeutics, Inc. Announces New Individual Patient Response Data Showed at the 2024 Winter Clinical Dermatology Conference - Hawaii	Jan. 14	CI
North American Morning Briefing : S&P 500 Futures -2-	Jan. 04	DJ
Mizuho Upgrades Arcutis Biotherapeutics to Buy From Neutral, Raises Price Target to $8 From $4	Jan. 03	MT
North American Morning Briefing : Stock Futures Extend Losses as FOMC Minutes Awaited	Jan. 03	DJ
Certain Restricted Stock Units of Arcutis Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023.	Dec. 18	CI
Certain Options of Arcutis Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023.	Dec. 18	CI
Certain Common Stock of Arcutis Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023.	Dec. 18	CI

Chart Arcutis Biotherapeutics, Inc.

Duration

Period

More charts

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Companyâs pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Arcutis Biotherapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.59 USD

Average target price

18 USD

Spread / Average Target

+109.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARCUTIS BIOTHERAPEUTICS, INC.	+165.94%	988M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.70%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-9.26%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs